Semnur Pharmaceuticals, Inc.
SMNROTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | $50.0M | — | — |
| Operating income | −$160.4M | −$1.6M | −$3.2M | — |
| Net income | −$160.4M | −$167,306 | $632,536 | −$419,390 |
| Total assets | $1.3M | $9.0M | $50.7M | $86.3M |
| Total liabilities | $22.1M | $10.4M | $8.5M | $4.2M |
| Equity | −$20.8M | −$10.4M | −$8.3M | $0 |
| EPS (diluted) | $-0.78 | $-0.02 | — | — |
| Shares out. | 230.2M | 200.0M | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 773.1%
- Return on assets
- −11918.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1641.6%
- Debt / equity
- —
- Book value / share
- $-0.09
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1516.51distress
- Accruals / assets
- −11482.1%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Scilex Holding CoActivist (13D)Oct 14, 2025
- Meteora Capital, LlcPassive (13G)Aug 14, 2025
- Td Securities (Usa) LlcPassive (13G)Aug 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Scilex Holding Co10% owner | Sep 23, 2025 | Sell | 11.9M | $16.00 |
| Denali Capital Global Investments Llc10% owner | Apr 11, 2022 | Buy | 510,000 | $10.00 |
| Xu Jiandong10% owner | Apr 11, 2022 | Buy | 510,000 | $10.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1,625 | 11.4 | -16.0% |
| Apr 30, 2026 | 1,935 | 20.2 | +10.6% |
| Apr 15, 2026 | 1,750 | 1000.0 | 0.0% |
| Mar 31, 2026 | 1,750 | 875.0 | 0.0% |
| Mar 13, 2026 | 1,750 | 56.5 | +7.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreementApr 23, 2026
- Director / officer changeMar 17, 2026
- Other material eventDec 3, 2025
- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Unregistered equity sale · Modified shareholder rights · Changed auditor · Change in control · Director / officer change · Amended charter or bylaws · Item 5.05 · Item 5.06 · Regulation FD disclosure · Other material eventSep 26, 2025
- Shareholder voteSep 4, 2025
- Entered a material agreement · Unregistered equity saleAug 22, 2025
- Other material eventAug 11, 2025
- Entered a material agreementJul 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.